Diphtheria Market
- Diphtheria Market size is anticipated to grow during the forecast period (2023–2032) owing the several companies such as Dynavax GmbH, GC biopharma, and others investigating their assets in the early and mid-late stage of development. With the expected approval of these therapies during the forecast period [2023–2032], the overall therapeutic market of diphtheria is likely to witness a rise at a significant CAGR.
- DelveInsight’s analyst estimates that the incidence of diphtheria continues to grow in the 7MM due to the rise in birth rate and growing population, advancements in vaccine delivery devices, and expansion of global immunization programs that are further expected to increase the diphtheria market.
- Disease awareness and preparedness lead to early diagnosis, timely treatment, and vaccination uptake. Additionally, the need for outbreak preparedness in areas with limited vaccine coverage or during potential outbreaks can drive demand for diphtheria-related products and services.
- Though the diphtheria treatment market is growing at a slow pace, there is an opportunity for pharmaceutical companies to focus on improving diphtheria traditional vaccines with new formulations and improved technologies such as the use of adjuvants or novel delivery systems that can enhance vaccine efficacy, safety, and convenience, leading to increased market demand.
- Furthermore, growing cases of airborne droplet infections and increased vaccine usage due to the COVID-19 pandemic have increased diphtheria market dynamics.
- On the other hand, the major challenges that restrain the diphtheria market growth include a lack of skilled staff to treat diphtheria patients, vaccine access and affordability, and a limited diagnostic capacity.
Request for Sample Page @ Diphtheria Market Report
DelveInsight’s report titled “Diphtheria Market Insights, Epidemiology, and Market Forecast – 2032” comprehensively analyzes diphtheria. The report includes a detailed examination of the historical and projected epidemiology data that includes incident cases of diphtheria segmented by age and type. The diphtheria market report offers an in-depth understanding of the various aspects related to the patient population, including diagnosis, prescriptions patterns, physician perspectives, market access, treatment, and future market developments for the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2019 to 2032.
To gauge the market’s overall potential and identify business opportunities, the report discusses current diphtheria treatment practices and algorithms and unmet medical needs.
| Study Period | 2019 to 2032 |
| Forecast Period | 2023-2032 |
| Geographies Covered |
|
| Diphtheria Market |
|
| Diphtherias Market Size | |
| Diphtheria Companies | GlaxoSmithKline, Sanofi Pasteur, Dynavax GmbH, GC biopharma, Tetanus Toxin Pertussis Toxin, Haemophilus influenzae Lipooligosaccharide, Bordetella pertussis Pertactin, Hemagglutinin, and others |
| Diphtheria Epidemiology Segmentation |
|
Diphtheria Treatment Market
Diphtheria Overview
Diphtheria is a highly contagious bacterial infection caused by the bacterium Corynebacterium diphtheriae. It primarily affects the respiratory system and can also cause damage to the heart, nervous system, and other organs if left untreated. The major virulence determinant of C. diphtheriae is diphtheria toxin, a bacteriophage-encoded protein. The infection is usually spread through respiratory droplets, such as coughing or sneezing, from infected individuals. Symptoms of the disease vary depending on the site of infection; however, sore throat, mild fever, and weakness are a few initial symptoms. Diphtheria most commonly affects children under the age of 5 years and adults over 70 years of age. This is primarily due to the higher chance that patients in these age groups have not had a vaccination or booster. The diagnosis is based on clinical presentation, laboratory tests, and identifying the bacteria or its toxin. Diphtheria can be prevented through vaccination. The most common vaccine used is the DTP vaccine, which protects against diphtheria, tetanus, and pertussis (whooping cough). Booster doses are recommended to maintain immunity throughout life. Further, prompt treatment is crucial for diphtheria. The primary treatment involves administering antitoxin to neutralize the diphtheria toxin and antibiotics to eradicate the bacteria.
Diphtheria Diagnosis
Diagnosing and treating diphtheria typically involves several steps, including the identification of risk factors, laboratory testing, lifestyle modifications, and, if necessary, medication interventions.
The cornerstone of diphtheria diagnosis is laboratory testing and clinical evaluation conducted to confirm the diagnosis of diphtheria. This typically involves collecting specimens from the throat or other affected areas and sending them to a laboratory for culture and identification of the bacterium C. diphtheriae.
Diphtheria Treatment Landscape
The treatment approach for diphtheria typically involves a combination of interventions to eliminate the bacterial infection, neutralize the toxin produced by the bacteria, and provide supportive care. Diphtheria antitoxin (DAT) in combination with antibiotics is used.
Diphtheria Epidemiology
The Diphtheria epidemiology section provides insights into the historical and current diphtheria patient pool and forecasted trends for seven individual major countries. It recognizes the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.
The epidemiology section of the diphtheria market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
Key Findings
- “As per the World Health Organization (WHO) (2016), the incidence of diphtheria is low. Diphtheria is very rare; the incidence in 2015 was approximately 0.07 individuals per 100,000.”
- “According to the Centers for Disease Control and Prevention (CDC) (2022), the overall case-fatality rate for diphtheria is 5–10%, with higher death rates (up to 20%) among persons younger than 5 and older than 40 years of age. The incubation period is usually 2–5 days, with a range of 1–10 days.”
- “According to the American Society of Microbiology (2022), those who had received a diphtheria booster were 54% less likely, and those who had received a tetanus booster were half as likely to develop severe COVID-19.”
- “According to the European Centre for Disease Prevention and Control (ECDC) (2022), diphtheria is a rare disease in the EU/EEA. An average of 52 cases were reported annually across the EU/EEA to ECDC between 2016 and 2020. Around 50% of reported cases were caused by C. diphtheria. Of the 128 cases caused by C. diphtheriae reported between 2016 and 2020, 60 were cutaneous, 25 respiratory, and one had both a cutaneous and respiratory presentation.
Diphtheria Market Outlook
The treatment and management of diphtheria involve a combination of vaccines and the use of medications. The diphtheria market is segmented based on the product type and treatment. Based on product type, the market already has diphtheria toxoid and pertussis (Dtap), tetanus toxoid (TT), and tetanus-diphtheria (Td), while based on treatment the use of antitoxin, antibiotics, and macrolides have been observed in patients with diphtheria.
Vaccination is the primary approach to prevent diphtheria and is usually administered as part of a combination vaccine, such as the DTP vaccine (diphtheria, tetanus, pertussis). The vaccine stimulates the immune system to produce antibodies against the diphtheria toxin, providing immunity against the disease. Multiple vaccine doses are recommended, typically starting in infancy and followed by booster doses throughout life. For individuals diagnosed with diphtheria, treatment often involves the use of diphtheria antitoxin (DAT). DAT is derived from the blood of animals immunized against diphtheria toxin and contains antibodies that neutralize the toxin produced by the bacteria. DAT administration can help prevent the spread of the toxin and reduce the severity of the disease.
Alongside DAT, antibiotics are also prescribed to treat diphtheria. Antibiotics, such as penicillin or erythromycin, are used to eliminate the bacteria from the body, reduce transmission to others, and prevent complications. Antibiotic treatment is usually administered for a specified duration, depending on the severity of the infection and the individual’s response. Moreover, an early diagnosis and prompt initiation of treatment can manage diphtheria. A specific treatment regimen is based on the severity of the disease and individual patient factors.
According to DelveInsight, the Diphtheria market in the 7MM is expected to change significantly during the study period 2019–2032.
Diphtheria Drug Chapters
Diphtheria Marketed Drugs
VAXELIS: Sanofi Pasteur
VAXELIS, manufactured by Sanofi Pasteur, is a hexavalent vaccine or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect children against diphtheria, tetanus, pertussis, poliomyelitis, Hemophilic B, and hepatitis B, which is used in more than 90 countries around the world including in Europe, Canada, Australia, and New Zealand.
In February 2016, marketing approval in the EU was granted to Vaxelis, while in December 2018, the US FDA licensed DTaP-IPV-Hib-HepB (Vaxelis) for use as a three-dose series in infants at ages 2, 4, and 6 months.
ADACEL: Sanofi Pasteur
ADACEL, manufactured by Sanofi Pasteur, is a Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine) used in adults, adolescents, and children aged 4 years and older as a booster following primary immunization. It is a suspension for intramuscular injection.
In June 2005, ADACEL was licensed in the US for use in adults and adolescents 10–64 years of age. FDA also approved ADACEL for use during pregnancy.
Diphtheria Emerging Drugs
The currently available treatments for diphtheria aim to mitigate the complications associated with the condition. The Diphtheria market dynamics are expected to change, primarily due to increased healthcare spending worldwide. Diphtheria Market players such as GlaxoSmithKline, MassBiologics, Sanofi Pasteur, Dynavax GmbH, GC Biopharma, and others are actively involved in developing Diphtheria treatments.
GC3111: Green Cross Corporation
GC3111 is an investigational diphtheria toxin that inhibits eukaryotic protein synthesis and acts as an immune stimulant. A bacterial vaccine is administered via the intramuscular route. GC 3111A is still in Phase II trials for diphtheria, pertussis, and tetanus.
DV2-TDAP-01: Dynavax
DV2-TDAP-01, manufactured by Dynavax Technologies, is a DTaP vaccine used for tetanus, diphtheria, and pertussis. The company completed a Phase I trial, demonstrating the vaccine candidate was well tolerated without safety concerns. Additionally, immunogenicity results in adults were consistent with our expectations and supported our plan to continue advancing the vaccine program.
| Drug | MoA | RoA | Company | Phase |
| GC3111 | Immune-stimulant | Intramuscular | Green Cross Corporation | II |
| DV2-TDAP-01 |
Diphtheria Toxin inhibitors | Intramuscular |
Dynavax | I |
| XXX | XX | XX | XX | XX |
Note: Detailed emerging therapies assessment will be provided in the final report…
Diphtheria Market Segmentation
DelveInsight’s ‘Diphtheria Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a detailed outlook of the current and future diphtheria market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Diphtheria Market Size by Countries
The total Diphtheria market size is analyzed for individual countries (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan). The United States accounted for a larger portion of the 7MM market for diphtheria in 2022 due to the high incidence of the condition and the higher cost of treatments. With the potential early entry of new products, this dominance is predicted to continue.
Diphtheria Market Size by Therapies
To depict each nation’s distinct historical and projected market shares, the diphtheria market is separated by therapies and medication classes. Ongoing research focuses on a novel mode of action to improve the quality of life for individuals with diphtheria.
The market for diphtheria therapies includes vaccines, such as the DTP vaccine (diphtheria, tetanus, pertussis), and medications used to treat diphtheria, such as diphtheria antitoxin and antibiotics.
Despite the presence of marketed vaccines, diphtheria and other infections caused by potentially toxigenic corynebacteria continue to play major roles as a lethal resurgent infectious disease.
However, educating patients and creating awareness with improved vaccine access and affordability can improve diphtheria market growth.
Note: Detailed market segment assessment will be provided in the final report…
Diphtheria Market Access and Reimbursement
DelveInsight’s ‘Diphtheria Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a descriptive overview of the market access and reimbursement scenario of diphtheria.
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current Diphtheria market trends and fulfill gaps in secondary findings, we interview KOLs and SMEs’ working in the Diphtheria domain. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or diphtheria market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the diphtheria unmet needs.
Diphtheria: KOL Insights
DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Nantes Université in France, the Department of Immunology and Respiratory at Duke University Medical Center, and Durham in the US.
“There are four kinds of vaccines available to provide protection against DT (diphtheria and tetanus) in the US, so it is recommended that children who received four doses before their fourth birthday receive a fifth dose of DTaP (diphtheria, tetanus, and acellular pertussis) vaccine before starting school.”
“Lifestyle modifications, including adopting face masks and regular sanitization after the pandemic, has been a common approach against all airborne droplet diseases, including Diphtheria.”
Note: Detailed assessment of KOL Views will be provided in the full report of diphtheria…
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Diphtheria Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Diphtheria Pipeline Development Activities
The Diphtheria report provides insights into Diphtheria Clinical Trials within Phase II and Phase III stages. It also analyses Diphtheria Companies involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, patent details, and other information for emerging diphtheria therapies.
Diphtheria Report Insights
- Diphtheria Patient Population
- Diphtheria Therapeutic Approaches
- Diphtheria Pipeline Analysis
- Diphtheria Market Size and Trends
- Diphtheria Market Opportunities
- Impact of Upcoming Diphtheria Therapies
Diphtheria Report Key Strengths
- 10 years Forecast
- The 7MM Coverage
- Diphtheria Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Diphtheria Market
- Diphtheria Drugs Uptake
Diphtheria Report Assessment
- Diphtheria Current Treatment Practices
- Diphtheria Unmet Needs
- Diphtheria Pipeline Product Profiles
- Diphtheria Market Attractiveness
- Diphtheria Market Drivers
- Diphtheria Market Barriers
Key Questions Answered In the Diphtheria Market Report
- What are the key findings of the market across the 7MM, and what country will have the largest Diphtheria market size during the forecast period (2023–2032)?
- What are the major causes of diphtheria, and how is it diagnosed?
- What are the marketed drugs for diphtheria in the 7MM?
- At what CAGR is the diphtheria market, and is epidemiology expected to grow in the 7MM during the forecast period (2023–2032)?
- How would the unmet needs impact the Diphtheria market dynamics and subsequently influence the analysis of related trends?
- What would be the forecasted patient pool of diphtheria in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- What are the current treatment guidelines and options for Diphtheria in the US, Europe, and Japan?
- What are the latest advancements in novel therapies, targets, mechanisms of action, and technologies being developed to address the limitations of existing therapies for diphtheria?
- How many companies are currently engaged in the development of therapies for the treatment of diphtheria?
Frequently Asked Questions
What is diphtheria?
Diphtheria is a contagious and potentially life-threatening bacterial infection. It is caused by infection with a toxin-producing strain of C. diphtheriae or, more rarely, Corynebacterium ulcerans or Corynebacterium pseudotuberculosis. It occurs in two forms: Respiratory diphtheria and cutaneous diphtheria.
How is diphtheria transmitted?
Diphtheria is primarily transmitted through respiratory droplets from an infected person. When an infected person coughs, sneezes, or even talks, tiny droplets containing the diphtheria bacteria can be released into the air. These droplets can then be inhaled by others who are close to the infected person.
What are the types of Diphtheria Treatment available in the market?
Different types of treatment approaches involve the use of tetanus immune globulin, tetanus toxoid, diphtheria toxoid, and others.
Is there any approved drug for diphtheria?
Yes, there are several drugs approved for diphtheria, including LEQVIO. In December 2021, the US FDA approved LEQVIO (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C).
How the market of diphtheria is expected to change during the forecast period (2023–2032)?
With the recently launched drug and anticipated approval of therapies during the forecast period, it is expected to drive the market with a significant CAGR.
How is the market size estimated in the forecast report?
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.
Does the report provide insights into the competitive landscape of the market?
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Diphtheria market.